Mouse Pseudomonas Aeruginosa Antigen O5 Monoclonal Antibody

Pseudomonas Aeruginosa antigen O5 Mouse Monoclonal Antibody

Cat. Num. AAA77829

• Applications: Immunoprecipitation, Western Blot, ELISA
• Synonyms: Pseudomonas Aeruginosa Antigen O5, Antibody; Pseudomonas Aeruginosa antigen O5 Mouse Monoclonal Antibody; P. Aeruginosa antigen O5, serotype 5; anti-Pseudomonas Aeruginosa Antigen O5 antibody

• Host: Mouse
• Clonality: Monoclonal
• Isotype: IgM kappa
• Clone Number: MF15-4
• Specificity: The antibody recognizes the O5 serotype of Pseudonomas aeruginosa and it might cross-react with O2, O16, 018 and O20.
• Form/Format: Purified, stored in PBS, pH 7.4 and lyophilized.

• Applicable Applications for anti-Pseudomonas Aeruginosa Antigen O5 antibody: IP (Immunoprecipitation), WB (Western Blot), ELISA, Agglutination
• Immunogen: Whole bacteria strain O5
• Preservative: None
• Target: Pseudomonas Aeruginosa antigen O5
• Target alias: P. Aeruginosa antigen O5, serotype 5
• Preparation and Storage: Lyophilized antibodies can be kept at 4°C for up to 3 months and should be kept at -20°C for long-term storage (2 years). To avoid freeze-thaw cycles, reconstituted antibodies should be aliquoted before freezing for long-term (1 year) storage (-80°C) or kept at 4°C for short-term usage (2 months). For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made with the assay buffer. After the maximum long-term storage period (2 years lyophilized or 1 year reconstituted) antibodies should be tested in your assay with a standard sample to verify if you have noticed any decrease in their efficacy. To limit antibody loss or degradation, BSA (final concentration 0.02%) and sodium azide (final concentration 0.02%) can be added to the suggested first dilution. It is important to first verify if those preservatives are compatible with your assay.

Related Product Information for anti-Pseudomonas Aeruginosa Antigen O5 antibody

Target Background:
Pseudomonas aeruginosa is a Gram-negative bacterium widely distributed in nature and causing opportunistic infections in humans. P. aeruginosa is an important bacterial pathogen of nosocomial (hospital derived) infections, and it can also cause life threatening diseases in patients with cancer, burn wounds, cystic fibrosis and those that have received immunosuppressive therapy. Classification of P. aeruginosa isolates is an important and routine task in hospitals. The basis for the serotyping system for P. aeruginosa is the differences among the O antigen side chains of lipopolysaccharide (LPS). A large number of O antigen side chains have been established by various investigators around the world which led to the creation of a standardized serotyping system known as the International Antigenic Typing Scheme (IATS) with twenty characterized 0 serotype strains of P. aeruginosa.

References

1. Lam JS-LPS quantitation procedures. 2. Kaluzny K-Coexistence of two distinct versions of O-antigen polymerase, Wzy-alpha and Wzy-beta, in Pseudomonas aeruginosa serogroup 02 and their contribution. 3. Daniels C-Pseudomonas aeruginosa 0-antigen chain length is determined before ligation to lipid A core. 4. Newton GJ-Three-component-mediated serotype conversion in Pseudomonas aeruginosa by bacteriophage D3. 5. Rahim R-Involvement of the rml locus in core oligosaccharide and 0 polysaccharide assembly in Pseudomonas aeruginosa. 6. Dasgupta T-Characterization of lipopolysaccharide-deficient mutants of Pseudomonas aeruginosa derived from serotypes 03,05, and 06. 7. Lightfoot J and Lam JS-Chromosomal mapping, expression and synthesis of lipopolysaccharide in Pseudomonas aeruginosa: a role for guanosine diphospho (GDP)-D-mannose. 8. Lam JS-Monoclonal antibodies as probes to examine serotype-specific and cross-reactive epitopes of lipopolysaccharides from serotypes 02, 05, and 016. 9. Lam MY-Occurrence of a common lipopolysaccharide antigen in standard and clinical strains of Pseudomonas aeruginosa. 10. Lam JS-Visualization of Pseudomonas aeruginosa 0 antigens by using a protein A-dextran-colloidal gold conjugate with both immunoglobulin G. 11. Lam JS-Production and characterization of monoclonal antibodies against serotype strains of Pseudomonas aeruginosa.